Chemistry:Mubritinib
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H23F3N4O2 |
| Molar mass | 468.480 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.[1][2][3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.[4]
See also
References
- ↑ Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. 2005. doi:10.1385/1-59259-962-1:001. ISBN 1-58829-384-X.
- ↑ The organic chemistry of drug synthesis. New York: Wiley. 1977. ISBN 0-470-10750-2. https://books.google.com/books?id=N6OAhuiHqiIC&pg=PA108.
- ↑ Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. 2008. ISBN 978-0-470-19039-5. https://books.google.com/books?id=fEwl6Qev-mUC&pg=PA311.
- ↑ Clinical trial number NCT00034281 for "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2" at ClinicalTrials.gov
 |  |
